154 results
8-K
REPL
Replimune Group Inc
26 Mar 24
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
7:33am
, will transition into the newly created role of the lead independent director of the Board (the foregoing, collectively, the “CEO Transition”).
In addition
8-K
EX-99.1
REPL
Replimune Group Inc
8 Jan 24
Regulation FD Disclosure
8:00am
is by investigator assessment; the primary analysis from the study will be by blinded, independent central review. BOR=best overall response 1 in 3 … for the combination arm; treatment duration for cemiplimab-only arm is 54 weeks Key Endpoints Dual independent primary endpoints: Complete Response Rate
8-K
REPL
Replimune Group Inc
8 Jan 24
Regulation FD Disclosure
8:00am
are finalized and publicly released. The Company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, has not audited, reviewed
8-K
EX-99.1
c87c3
5 Dec 23
Other Events
7:19am
8-K
EX-99.1
mj88dy6drqtj 78
7 Nov 23
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
8:15am
8-K
7u97vpw
7 Sep 23
Submission of Matters to a Vote of Security Holders
9:17am
S-3ASR
4xtcn9l3ffky4ae41fi
3 Aug 23
Automatic shelf registration
8:45am
S-3ASR
EX-5.1
pgpftm06wh729b84
3 Aug 23
Automatic shelf registration
8:45am
S-3ASR
EX-1.2
g3pyz6b53
3 Aug 23
Automatic shelf registration
8:45am
S-3ASR
EX-4.7
7gg0myrrk ot
3 Aug 23
Automatic shelf registration
8:45am
S-3ASR
EX-23.2
ahp pmchklgmy
3 Aug 23
Automatic shelf registration
8:45am
8-K
EX-99.1
o8lfypfxu5 vk
3 Aug 23
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
8:09am
DEFA14A
qyu 8ph8emdcbm5wet
26 Jul 23
Additional proxy soliciting materials
5:06pm